Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Virgin Galactic Holdings Inc SPCE

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which offers access to space for private individuals, researchers, and government agencies. The Company’s operations include design and development, manufacturing, ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The Company has developed a portfolio of proprietary technologies that are embodied in the specialized vehicles that it has created to enable commercial spaceflight. These technologies include carrier aircraft, the mothership; its spaceships; its hybrid rocket motor, and its safety systems. Its Carrier Aircraft-The Mothership is a twin-fuselage, custom-built aircraft designed to carry spaceships up to an altitude of approximately 45,000 feet, where the spaceship is released for its flight into space. Its Virgin Galactic spaceships are reusable with the capacity to carry pilots and private astronauts, research experiments and researchers.


NYSE:SPCE - Post by User

Post by Shierleyon Jun 03, 2022 5:46am
138 Views
Post# 34728814

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>